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Abstract
Background: Total knee arthroplasty (TKA) is common, effective, and cost-effective. Innovative implants promising reduced
long-term failure at increased cost are under continual development. We sought to define the implant cost and
performance thresholds under which innovative TKA implants are cost-effective.
Methods: We performed a cost-effectiveness analysis using a validated, published computer simulation model of knee
osteoarthritis. Model inputs were derived using published literature, Medicare claims, and National Health and Nutrition
Examination Survey data. We compared projected TKA implant survival, quality-adjusted life expectancy (QALE), lifetime
costs, and cost-effectiveness (incremental cost-effectiveness ratios or ICERs) of standard versus innovative TKA implants. We
assumed innovative implants offered 5–70% decreased long-term TKA failure rates at costs 20–400% increased above
standard implants. We examined the impact of patient age, comorbidity, and potential increases in short-term failure on
innovative implant cost-effectiveness.
Results: Implants offering $50% decrease in long-term TKA failure at #50% increased cost offered ICERs ,$100,000
regardless of age or baseline comorbidity. An implant offering a 20% decrease in long-term failure at 50% increased cost
provided ICERs ,$150,000 per QALY gained only among healthy 50–59-year-olds. Increasing short-term failure, consistent
with recent device failures, reduced cost-effectiveness across all groups. Increasing the baseline likelihood of long-term TKA
failure among younger, healthier and more active individuals further enhanced innovative implant cost-effectiveness
among younger patients.
Conclusions: Innovative implants must decrease actual TKA failure, not just radiographic wear, by 50–55% or more over
standard implants to be broadly cost-effective. Comorbidity and remaining life span significantly affect innovative implant
cost-effectiveness and should be considered in the development, approval and implementation of novel technologies,
particularly in orthopedics. Model-based evaluations such as this offer valuable, unique insights for evaluating technological
innovation in medical devices.
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Many medical devices are marketed with claims of reduced
long-term device failure and/or adverse events. Such claims are
often based upon laboratory or ex vivo data extrapolated to long-
term outcomes in humans and cannot be evaluated with short-
term trials. Given the costs and limitations of prospectively
collecting long-term efficacy data on innovative devices, simulation
modeling is an ideal methodology to evaluate current technologies
and anticipate potential health and economic consequences of
future technologies.
Total knee arthroplasty (TKA) implant innovation provides an
informative case study for examining the impact of medical device
innovation on healthcare costs [1]. Over 620,000 TKAs were
performed in the US in 2009, predominantly for end-stage
osteoarthritis (OA) [2]. TKA inpatient costs exceed $9 billion per
year, the highest aggregate cost among the 10 fastest growing
procedures [3]. Over 85% of recipients have functional improve-
ment after TKA [4–7], and TKA is highly cost-effective [8].
Fueled by this success and trends suggesting that TKA
recipients are younger, heavier, more active, and surviving longer
after TKA than previously [2,9–11], over 35 TKA systems or
components have been approved by the Food and Drug
Administration (FDA) each year for the last decade through the
510(k) clearance process [12]. This process allows approval of
perceived low-risk medical devices based upon claims of similarity
to existing approved devices and likely incentivizes incremental
improvements. Indeed, most claims of improved device durability
are based upon ex vivo studies [13–19], rather than clinical trials,
and such innovations come at a price, as newer implants are more
costly [20–22].
Trade-offs between incremental improvements and their costs
are poorly understood. With rising healthcare costs, it is critical to
examine the value of technological advancements over existing
devices. TKA is an ideal example for studying the cost/benefit
trade-offs for medical devices, particularly those that offer quality
of life improvement rather than immediate survival benefit. Given
the costs and limitations of prospectively collecting long-term
efficacy data on innovative medical devices, such as TKA
implants, simulation modeling is an ideal methodology to evaluate
current technologies and anticipate potential health and economic
consequences of future technologies.
We sought to examine cost/benefit trade-offs and present the
long-term economic implications associated with the use of
innovative TKA implants using a simulation modeling approach.
Specifically, we sought to define the conditions, including the
patient characteristics, implant performance, and cost assumptions,
under which innovative TKA implants might offer clinical benefit
and good value for additional dollars spent versus those scenarios
under which innovative implants would result in greater costs and/
orunfavorableeconomicvalue.More broadly,ouranalysisprovides
a paradigmatic case study of the impact of medical device
innovation on clinical efficacy and cost-effectiveness.
Methods
Ethics Statement
The study was approved by the Institutional Review Board of
Brigham & Women’s Hospital. Our research was conducted
entirely in the U.S.A. No participants were involved and so no
consent was required.
Analytic Overview
We used a validated, previously published computer simulation
model of knee OA natural history and management (the
Osteoarthritis Policy or OAPol model) [23,24] to forecast surgical,
clinical and economic outcomes associated with ‘‘innovative’’
TKA implants (e.g., highly crossed-linked polyethylene or other
innovative biomaterials) as compared with ‘‘standard’’ implants
(i.e., an ultra-high molecular weight all polyethylene tibial
component) [25] in persons with end-stage knee OA. Laboratory
data indicate these newer implants experience less wear, implying
greater durability [14,19]. Our primary analysis varied implant
durability and cost among different patient cohorts. Incremental
cost-effectiveness ratios (ICERs), defined as the incremental
benefits in additional quality-adjusted life expectancy (QALE)
divided by the incremental costs, were estimated for innovative
compared with standard implants.
OAPol Model
The OAPol model is a state-transition simulation model that
uses a series of annual transitions between health states to describe
the natural history and clinical management of knee OA. Pain,
comorbidity, treatment, quality of life, and resource use are used
to define discreet health states. These characteristics also influence
further disease progression, response to treatments, development
of additional comorbidities, and mortality. The model is imple-
mented as a Monte Carlo simulation, meaning a random number
generator and a set of estimated probabilities are used to
determine the state-to-state pathway followed by each simulated
patient. Each patient’s course is then tracked until death, and large
numbers of individual simulations are combined to estimate
population outcomes and costs. This model has been used to
estimate TKA cost-effectiveness [8], knee OA burden [24], and
quality-adjusted life-years (QALYs) lost due to obesity and knee
OA [23]. Model specifications, validation, and data sources have
been previously published [1,23] and are supplemented in the
Technical Appendix S1.
Study Population
We considered a population of individuals with end-stage
(Kellgren-Lawrence grade IV) symptomatic knee OA at baseline.
We considered four separate age and comorbidity cohorts to
explore the impact of these characteristics on implant cost
effectiveness. The four cohorts included 50–59 year-olds with
and without comorbidity at the time of TKA and 70–79 year-olds
with and without comorbidity at the time of TKA (see Population
Demographics below for further explanation). We selected these
age stratifications because while, historically, most US TKA
recipients were in their 70 s, individuals under 65 years old
represent the most rapidly growing group among TKA recipients
[11].
Input Parameters
Model input parameters are listed in Table 1 and summarized
below. Further details are also provided in the Technical
Appendix S1.
Population demographics. We derived baseline distribu-
tions of sex, race, and ethnicity from 2000 Medicare claims data
[26] and validated these parameters against a nationally repre-
sentative sample of TKR recipients [2]. We dichotomized the
baseline presence of medical comorbidities as ‘‘healthy’’ (no
comorbidities) versus ‘‘with comorbidity’’ (including baseline
obesity, cardiovascular disease, and other, non-OA musculoskel-
etal disorders). Cohorts ‘‘with comorbidity’’ experienced higher
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Parameter Estimates Source
Quality of Life (in QALYs)
,65 years old 65+ years old
Healthy With
Comorbidity
Healthy With
Comorbidity
Knee Pain - (No pain relief from TKA) 0.806 0.679 0.884 0.757 NHANES 2005–2008 [33,34], Losina
et al, 2011
No Knee Pain - (Pain relief from TKA)
{ 0.952 0.867 0.943 0.858 [23]
Surgical AE
` 0.60 Fisman et al, 2001 [32]
Medical AE Pneumonia Myocardial Infarction Pulmonary Embolism
0.60 0.65 0.50 Taylor et al, 2009 [29],
Melinkow et al, 2008 [30], Weaver
et al, 2001 [31]
Costs (in 2010 US$)
Healthy With Comorbidity
Underlying Medical Costs 986–1,205 2,388–2,860 Lee et al, 2001 [35], NHANES 2005–
2008 [33,34]
Analgesic Treatment
1 333 Red Book 2008 [36]
TKA Costs Primary TKA Revision TKA
First Year 23,903 28,195 Losina et al, 2009 [8]
Implant 5,414 Mendenhall, 2004 [37]
Annual Follow-Up 103 CMS
|| 2008 [39], Teeny et al, 2003 [40]
Surgical AE 21,213 HCUP 2008 [2]
Medical AE Pneumonia Myocardial Infarction Pulmonary Embolism
10,388 18,478 12,090 HCUP 2008 [2]
, Standard Implants ,
TKA Efficacy & Adverse Events
Short-Term
" Long-Term
**
Primary TKA Revision TKA Primary TKA Revision TKA
Technical Failure
{{ % 1.1 1.1 1.36 1.36 Losina et al, 2009 [8]
Pain Relief Success
`` % 86.2 74.3 96.0 94.4 Katz et al, 2007 [7]
Adverse Events
11 %
Surgical 0.37 0.67 22
Medical
Pneumonia 1.27 1.27 22
Myocardial Infarction 0.75 0.75 22Katz et al, 2004 [27]
Pulmonary Embolism 0.74 0.74 22
Death from AE 0.63 0.96 22
, Innovative Implants ,
TKA Efficacy
Short-Term Long-Term
Technical Failure % (Range) 1.1 (1.1–5.5) 0.4–1.1
*** Losina et al, 2009 [8]
Pain Relief Success % (Range) 86.2 (75.9–100) 96.0 Katz et al, 2007 [7]
Costs (in 2010 US$)
TKA Costs
First Year 24,986–45,559 Losina et al, 2009 [8]
Placing a Price on Medical Device Innovation
PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e62709mortality, reduced quality of life, and increased underlying
medical costs, compared to ‘‘healthy’’ cohorts.
Surgical outcomes: TKA Efficacy and Adverse Events for
Standard Implants. Surgical outcomes consisted of TKA
efficacy and adverse event (AE) rates which were derived from
published estimates [7,8,27]. Standard TKA efficacy was com-
prised of pain relief efficacy (defined as the percentage of
individuals achieving pain relief) and the absence of technical
failure (defined as the percentage of individuals requiring or
qualifying for revision surgery due to mechanical failure).
Experiencing recurrent knee pain following surgery resulted in a
decrement in quality of life as noted below. Both pain relief and
technical failure were further divided into first year (‘‘short-term’’)
versus subsequent year (‘‘long-term’’) rates.
The primary clinical outcome in the model consisted of QALE,
a patient-relevant outcome assessment validated for use in a wide
range of clinical conditions, including knee osteoarthritis and
individuals undergoing TKA. QALE represents an ideal metric for
assessing long-term outcomes following TKA as this procedure is
focused primarily on improving function and reducing pain, thus
directly affecting quality of life. Scores from the SF-36 question-
naire were transformed into quality of life weights using published
methods [8,28]. Quality of life estimates for TKA-related AEs
were derived from published literature [29–32]. Quality of life
valuations over time were influenced by the presence of pain, body
mass index (obese or non-obese) and number of comorbidities (0–
1, 2–3, or .3).
Economic outcomes: Costs. Underlying annual medical
costs, in 2010 US dollars, were stratified by age, presence of knee
pain and comorbidity and ranged from $986 to $2,860 [33–35].
An additional annual cost of $333 was added for individuals for
whom TKA did not provide pain relief to account for analgesic
treatment [36].
The cost of TKA (including hospital, physician, and rehabili-
tation costs) was estimated at $23,903 [8], of which the implant
cost represented $5,414, based on survey data from a national
sample of hospitals [37]. This estimate of implant cost is consistent
with the findings of a recent study utilizing data from sixty-one
hospitals in 2008 [38]. Annual follow-up cost for TKA (including a
physician visit and imaging) was determined from Medicare
reimbursement data and a national survey of orthopedic surgeons
[39,40].
Primary Analysis
We measured comparative value in constant (2010) US dollars
per QALY gained and reported all economic outcomes from a
modified societal perspective, adjusted for time value (with 3%
annual discounting), but excluding indirect costs [41]. We
estimated the proportion of each cohort surviving with their
original implant intact at 5, 10, 15, and 20 years after TKA. We
calculated the QALE and costs associated with each combination
of innovative TKA implant cost (20–400% over standard cost)
[21,37,42] and reduction in long-term implant failure rate (5–70%
decreases compared to standard implants) [14,19] in each of the
four primary patient cohorts. ICERs compared to standard TKA
were calculated for each combination of implant cost, long-term
implant failure rate, and patient cohort.
Sensitivity Analyses
Based upon recent data suggesting that younger TKA recipients
experience higher revision rates than older individuals [43],
presumably due to higher activity levels leading to higher wear, we
examined the impact of higher annual TKA failure rates (2.72–
5.44%, versus 1.36% baseline risk) among the healthy 50–59-year-
old cohort. We also examined the impact of increasing short-term
TKA failure consistent with recent orthopedic device failures
(100–500% increases in first-year technical failure) [44] while
simultaneously decreasing long-term failure (5–70%), as one might
anticipate from an innovative technology offering greater long-
term benefit at higher short-term risk. We examined the impact of
varying the proportion of patients achieving pain relief from
innovative TKA implants; we considered values ranging from an
8% decrease to a 20% increase, compared to standard TKA. We
also varied TKA cost [8], TKA offer and acceptance rates, and
recipient demographics.
Results
Effect of Innovative Implants on Patient and Implant
Survival
Patient survival 20 years following TKA ranged from 80.7%
among healthy 50–59-year-olds to 13.6% among 70–79-year-olds
with baseline comorbidity. Among healthy 50–59-year-olds,
64.9% survived and retained their primary TKA implant at 20
Table 1. Cont.
Parameter Estimates Source
Implant
{{{ 6,497–27,070 Mendenhall, 2004 [37]
*Further input parameters are provided in the online Technical Appendix and published literature (Suter 2011, Losina 2011).
{In order to capture significant pain, we defined pain as those individuals noting functional limitations. Quality of life estimates were derived from general population
data, not specifically from TKA recipients.
`Derived from data for quality of life in persons with prosthetic joint infection.
1Annual cost of analgesic treatment was added for individuals who did not achieve pain relief from their TKA.
||CMS=Centers for Medicare and Medicaid Services.
"Short-term refers to the first year following primary or revision TKA.
**Long-term refers to the annual proportion of individuals experiencing a TKA outcome or AE each year following the first year after primary or revision TKA.
{{Technical failure is the percentage of individuals who required or qualified for revision surgery due to mechanical failure of the prosthesis, with or without associated
symptoms.
``Pain relief success is the percentage of individuals achieving pain relief without technical failure. In instances of technical failure, pain relief was significantly less than
the values reported above.
11Adverse events (AEs) only occurred in the first year after primary or revision TKA.
***These values represent the range of failure rates used in the Primary Analysis (20–70% reductions in failure for innovative compared to standard implants). Standard
implants had long-term failure rates as high as 5.44% in the sensitivity analysis exploring the impact of higher long-term failure in healthy 50–59-year-olds, producing a
failure rate of 4.35% for an innovative implant offering a 20% decrease in long-term failure.
{{{The implant cost is included in the total first-year cost of TKA.
doi:10.1371/journal.pone.0062709.t001
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baseline comorbidity. In total, 17.8% of healthy 50–59-year-olds
and 9.4% of 70–79-year-olds with baseline comorbidity underwent
revision surgery within 20 years of their primary TKA.
Innovative implants offering a 5% reduction in long-term TKA
failure decreased the proportion of TKA recipients undergoing
subsequent revision by only 0.79% and 0.39% (absolute percent-
age points) over 20 years in healthy 50–59-year-olds and 70–79-
year-olds with comorbidity, respectively. Implants offering a 40%
decrease in long-term TKA failure decreased the percent of TKA
recipients undergoing revision by 6.29% among healthy 50–59-
year-olds and 3.28% among 70–79-year-olds with comorbidity.
An implant reducing long-term failure by 70% decreased revisions
by 11.32% among healthy 50–59-year-olds and 5.83% among 70–
79-year-olds with comorbidity.
Effect of Innovative Implants on QALE, Costs, and Cost-
Effectiveness
Remaining QALE and costs for standard and innovative
implants are reported in Table 2. QALE after standard TKA
ranged from 7.57 QALYs among 70–79-year-olds with baseline
comorbidity to 16.43 QALYs among healthy 50–59-year-olds.
Innovative TKA implants decreasing long-term TKA failure by
5% offered, on average, #0.01 additional QALYs (,four days)
compared to standard TKA among all four populations. Implants
decreasing long-term failure by 40% resulted in #0.06 additional
QALYs among 50–59-year-olds and 0.02 additional QALYs
among 70–79-year-olds. A 70% decrease in long-term failure
offered an average of 0.10 additional QALYs (,37 quality-
adjusted days) across the cohorts.
Remaining lifetime costs ranged from $42,186 in healthy 70–79-
year-olds to $82,524 among healthy 50–59-year-olds. Innovative
implants costing 20% to 400% above standard implants resulted in
$446 to $20,959 increases in lifetime costs. Greater reductions in
long-term failure always resulted in lower costs. Innovative
implants offering a 70% reduction in long-term failure at only
20% higher cost resulted in greater QALE but lower lifetime costs
than the standard implant in all four cohorts, suggesting such an
implant would be cost-saving compared to standard implants if
that level of TKA failure reduction could be achieved.
ICERs for innovative compared to standard implants varied
with changes in both long-term implant failure and implant cost.
Innovative implants costing at least three times more than a
standard implant yielded ICERs above $150,000 per QALY
gained in all populations except for healthy 50–59-year-olds, for
which the ICER was $81,493. Implants offering a 20% reduction
in long-term failure at 50% increased implant cost yielded ICERs
of $71,007 per QALY gained (compared to standard TKA)
among healthy 50–59-year-olds, $158,622 among 50–59-year-olds
with baseline comorbidity, $189,494 among healthy 70–79-year-
Figure 1. Proportion of population alive with original implant after Standard TKA by age and comorbidity. The estimated proportion
of the population surviving with a successful primary TKA implant are noted by black bars among each of the four cohorts at 5, 10, 15, and 20 years
after standard TKA. The dark grey bars represent the proportion of the population who have experienced technical TKA failure but have not
undergone revision either due to the fact that their failure has not been observed by either the patient or their physician or they have been offered
revision but refused. The light grey bars represent the proportion that has undergone revision TKA. As one moves from healthy 50–59-year-olds on
the left to those with baseline comorbidity to healthy 70–79-year-olds and finally 70–79-year-olds with comorbidity on the far right, fewer individuals
survive to experience TKA failure and therefore TKA revision. TKA=Total knee arthroplasty.
doi:10.1371/journal.pone.0062709.g001
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bidity. More favorable ICERs were obtained when we considered
a healthier, younger target population and when we assumed
cheaper, more effective innovative implants (Figure 2). This trend
persisted in the 60–69-year-old and 80–89-year-old cohorts
(Figure 1 in the Technical Appendix).
Sensitivity Analyses
Increasing the standard implant failure rate among healthy 50–
59-year-olds produced lower ICERs for innovative implants.
Tripling the standard failure rate among healthy 50–59-year-olds
from 1.36% to 4.08% reduced the ICER for an implant that
decreased failure by 20% at 50% greater cost from $71,007 to
$22,475ska per QALY gained.
Increasing short-term implant failure while simultaneously
reducing long-term failure decreased cost-effectiveness across all
cohorts (i.e., fewer innovative implants produced ICERs
,$100,000 compared to standard TKA; Figure 3). Doubling
short-term failure from 1.1% (the value for a standard implant) to
2.2% for an innovative implant offering a 20% reduction in long-
term failure at 50% increased cost raised the ICER from $71,007
to $141,022 per QALY gained among healthy 50–59-year-olds
and from $278,098 to $807,358 per QALY gained among 70–79-
year-olds with comorbidity. When the short-term failure rate was
doubled and reductions in long-term failure rates from innovative
implants were small, innovative implants offered similar or worse
QALE compared to standard implants, but at greater cost
(‘‘dominated’’ scenarios in Figure 3).
The impact of increasing age and comorbidity on innovative
implant cost-effectiveness could be offset by either greater
reductions in long-term TKA failure or improved pain relief after
TKA, as might be expected with an implant that offers both
technical (decreased long-term failure) and clinical (increased
likelihood of pain relief) benefits (Figure 2 in the Technical
Appendix). A 4% increase in the percentage of individuals
experiencing pain relief after TKA reduced the ICER for an
innovative implant offering a 70% reduction in long-term TKA
failure at twice the cost of a standard implant, from $147,106 to
$76,270 per QALY gained among 70–79-year-olds with baseline
comorbidity.
Varying standard TKA implant cost (compared to the base
assumption of $5,414) from $2,390 to $11,952 produced ICERs
among healthy 50–59-year-olds that ranged from $82 (for lowest
standard implant cost) to $92,272 (for highest standard implant
cost) per QALY gained for an innovative implant that costs twice a
standard implant and offers a 70% decrease in long-term failure.
Performing the same analysis among 70–79-year-olds with
baseline comorbidity produced ICERs ranging from $36,585 to
$386,828 per QALY gained when the cost of the standard implant
was similarly ranged (Figure 3 in the Technical Appendix).
Discussion
We used TKA to demonstrate how simulation modeling can
measure the value of new healthcare technologies. We quantified
the impact of implant cost and longevity, and recipient age and
comorbidity on innovative TKA implant cost-effectiveness. The
Table 2. Lifetime QALE, cost, and cost-effectiveness estimates associated with Standard and Innovative TKA.
Ages 50–59 Ages 70–79
% Decrease
in Long-
% Increase
in Implant Healthy* With comorbidity
{ Healthy* With comorbidity
{
Term Failure Cost Cost QALE ICER
` Cost QALE ICER
` Cost QALE ICER
` Cost QALE ICER
`
Standard TKA $61,589 16.43 2 $82,523 12.88 2 $42,186 8.57 2 $55,606 7.57 2
20% $62,508 16.44 $98,576 $83,443 12.88 $256,918 $43,152 8.57 $285,846 $56,568 7.58 $253,792
50% $64,135 16.44 $272,947 $85,042 12.88 $703,083 $44,734 8.57 $754,131 $58,136 7.58 $667,360
5% 100% $66,834 16.44 $562,378 $87,734 12.88 $1,454,320 $47,358 8.57 $1,530,912 $60,723 7.58 $1,349,707
200% $72,220 16.44 $1,139,780 $93,034 12.88 $2,933,511 $52,632 8.57 $3,091,912 $65,951 7.58 $2,728,599
400% $83,034 16.44 $2,299,170 $103,648 12.88 $5,895,966 $63,148 8.57 $6,204,194 $76,378 7.58 $5,478,685
20% $62,035 16.46 $15,392 $83,031 12.89 $38,457 $42,856 8.58 $56,394 $56,275 7.58 $82,829
50% $63,648 16.46 $71,007 $84,618 12.89 $158,622 $44,437 8.58 $189,494 $57,852 7.58 $278,098
20% 100% $66,352 16.46 $164,242 $87,283 12.89 $360,432 $47,069 8.58 $411,024 $60,453 7.58 $600,244
200% $71,754 16.46 $350,514 $92,614 12.89 $763,998 $52,333 8.58 $854,102 $65,675 7.58 $1,246,999
400% $82,548 16.46 $722,735 $103,245 12.89 $1,568,953 $62,861 8.58 $1,740,275 $76,103 7.58 $2,538,459
20% $60,290 16.53 Cost saving $81,486 12.93 Cost saving $41,846 8.61 Cost saving $55,308 7.60 Cost saving
50% $61,911 16.53 $3,114 $83,088 12.93 $12,082 $43,420 8.61 $28,197 $56,850 7.60 $47,443
70% 100% $64,615 16.53 $29,254 $85,757 12.93 $69,145 $46,058 8.61 $88,485 $59,463 7.60 $147,106
200% $70,019 16.53 $81,493 $91,079 12.93 $182,905 $51,328 8.61 $208,939 $64,694 7.60 $346,593
400% $80,814 16.53 $185,840 $101,741 12.93 $410,828 $61,858 8.61 $449,577 $75,108 7.60 $743,764
*No obesity or comorbidity at baseline.
{Baseline obesity, cardiovascular disease, and non-OA musculoskeletal disease.
`ICER=incremental cost-effectiveness ratio in 2010 US$ per quality-adjusted life-year (QALY) gained, compared with standard TKA. ‘‘Cost saving’’ indicates greater
QALYs achieved at a lower cost compared to standard TKA.
doi:10.1371/journal.pone.0062709.t002
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for revision resulted in quality of life gains as high as 0.10 QALY,
consistent with other medical device innovations, such as dual-
chamber pacemakers, which offer incremental QALE benefits of
0.14 QALY compared to standard pacemakers [45]. It is
important to note, however, that because the revision rates of
TKA with standard implants are already low, much of the
population may not experience any benefit from innovative
implants, while a small group of people may experience large
benefits by avoiding otherwise complex revision procedures.
Taken as an average across the whole population, innovative
TKA implants therefore offered smaller increases in QALE than
other novel therapeutics, such as dabigatran for stroke prevention
in atrial fibrillation, which provided 0.42 more QALYs than
warfarin, a four times greater QALE benefit than even the most
optimistic innovative TKA implant in our study [46]. Further,
these gains are attenuated in older populations or those with
greater comorbidity that may not survive long enough to benefit
from decrements in long-term TKA failure.
While there is no single accepted threshold below which a novel
therapy might be considered ‘‘cost-effective’’, the WHO Com-
mission on Macroeconomics and Health offers the following
guidance: interventions should be labeled ‘‘cost-effective’’ in a
given country if their ICER is less than three times that nation’s
per capita gross domestic product; interventions whose ICER is
less than the per capita GDP may be labeled ‘‘highly cost-
effective’’ [47,48]. The GDP in the US is roughly $50,000 [49],
suggesting that that innovative TKA implants offering at most a
15% reduction in long-term failure are unlikely to offer cost-
effective value to a broad range of patient populations. Such
implants would need to provide at least a 50% relative decrease in
actual TKA failure compared with standard implants to be
considered broadly cost-effective according to WHO standards.
Healthy 50–59-year-olds, those with the greatest anticipated life
expectancy among our four cohorts, received the most meaningful
clinical and economic benefit from decreasing the TKA failure
rate. In fact, if innovative implants could be proven to reduce true
long term TKA failure by at least 35% among this cohort, and if
such implants cost only 20% more than existing implants, they
might even offer a cost saving alternative to standard implants.
This finding was accentuated when we assumed that younger,
healthier TKA recipients had a higher baseline risk of revision
than older less healthy individuals, as recent data suggest [43].
However, the true efficacy of innovative implants is
poorly understood and, based upon recent experience with
metal-on-metal implants [22], might actually lead to increased,
rather than decreased TKA failure rates.
While implant cost and efficacy affected innovative TKA
implant cost-effectiveness, recipient comorbidity and remaining
life span also had a substantial impact. Our results suggest these
factors may be even more important if innovative implants lead to
increased short-term TKA failure, as one might expect with a
novel technology that requires the development of specific skills
and/or surgical experience to produce optimal results. When the
short-term failure risk is doubled for healthy 50–59 year olds, an
innovative implant with only a 10% reduction in late-term failure
led to worse QALE than standard implants. The results were even
less favorable in older and sicker cohorts (Figure 3). Despite
yielding acceptable ICERs under some scenarios, increases in
innovative implant survival offered at most a 11.32% absolute
reduction in the cumulative risk of revision among healthy
Figure 2. Implant cost and long-term TKA failure rate thresholds. Each shaded area represents implant cost increases (vertical axis) and
failure rate reductions (horizontal axis) required to achieve a given ICER range (see Legend contained in Figure) among the four primary cohorts.
ICER=incremental cost-effectiveness ratio in 2010 US$ per quality-adjusted life-year (QALY) gained, compared with standard TKA.
doi:10.1371/journal.pone.0062709.g002
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aged 70–79 with baseline comorbidity.
There are limitations to our analysis. We estimated proportional
decreases in TKA implant failure based upon laboratory studies of
tibial and acetabular bearing surfaces [14,19], which are unlikely
to correlate precisely with clinical TKA outcomes and likely
overestimate the true clinical benefit of innovative implants.
However, in addition to exploring a wide range of possible effects
of innovative implants on reducing TKA failure, we chose
conservative estimates and assumed laboratory wear underesti-
mates true failure our conservative estimates demonstrated that
innovative biomaterials require a minimum of 50–55% reduction
in true long-term failure to be considered broadly cost-effective.
Published studies suggest innovative hip implants may reduce
short-term in vivo wear rates between 40–72%, [50–53] but these
radiographic findings may not accurately reflect clinical outcomes
such as implant failure or the need for revision. Robust, long-term
clinical data on TKA implants are unavailable, which is one of the
advantages of simulation modeling in this area. As true TKA
failure rates are unlikely to be reduced as much as short-term ex
vivo knee or in vivo hip studies indicate, it is improbable that
existing innovative implants offer marked economic value across
all populations.
Increased activity levels among younger, healthier TKA
recipients, who may therefore be at greater risk of TKA failure,
may further enhance innovative implant cost-effectiveness. How-
ever, we did not model dynamic decreases in TKA failure as an
individual ages, so our model likely overestimates the cost-
effectiveness of innovative implants under such assumptions. In
contrast, our base implant cost estimate may exceed the average
cost experienced by some hospitals [54], thereby underestimating
cost-effectiveness. Since TKA cost-effectiveness is sensitive to
implant cost, TKA innovations may be more or less cost-effective
depending upon the implant cost each hospital pays, producing
variability in value according to the negotiated cost [21]. While we
did not assess the impact of surgical technique on cost-
effectiveness, we did examine the possibility that innovative
technology might offer greater short-term failure due to the
potential for increased technical complexity associated with novel
devices. We also did not consider that the decision, from a
patient’s or society’s perspective, to adopt an innovative implant
today is to forgo the option of an even better implant tomorrow.
However, similar limitations are likely to affect the evaluation of
any innovative medical device and can be addressed by sensitivity
analyses to assess the impact of data uncertainty.
The FDA 510(k) clearance process has been criticized for
insufficient safety oversight and suppressing innovation through
incentivizing incremental gains [44,55]. Limited oversight of
medical device approval combined with economic and other
incentives serve to speed technology adoption [56]. However,
recent data demonstrate expedited approval is associated with
increased rates of high-risk product recalls [57]. Our analyses
suggest that small, incremental improvements in device longevity
may have little to no effect on QALE and cost-effectiveness,
Figure 3. Implant cost and long-term TKA failure thresholds in a scenario where the base short-term failure rate doubles. Each
shaded area represents implant cost increases (vertical axis) and failure rate reductions (horizontal axis) required to achieve a given ICER range (see
Legend contained in Figure) among the four primary cohorts in 2010 US$ per quality-adjusted life year (QALY) gained, compared with standard TKA.
Areas with black and white diagonal lines indicate assumptions under which innovative implants offer lower QALE for greater cost compared to
standard implants (i.e., such an innovative implant is ‘‘dominated’’ by the standard implant).
doi:10.1371/journal.pone.0062709.g003
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redesigning the 510(k) approval process [58]. Furthermore,
extensive recent data demonstrate that not all innovative implant
technologies will lead to actual improvements in longevity, and
some, such as metal-on-metal hip implants, may even lead to
worse long-term outcomes [22,59–62]. Innovative implants
providing no clinical benefit at an added cost would not be cost-
effective. Decisions as to the marketing, use and reimbursement of
medical devices are currently being made without robust outcomes
data to guide decision making. Our approach serves as a model for
evaluating a wide range of innovative technologies.
Because innovative implant technologies are released at about a
rate of 30 per year [11], surgeons and hospitals are often faced
with choices of whether to use specific innovative devices. These
devices may utilize one or more innovative technologies, such as
cementless fixation, rotating or sliding bearing inserts, novel
biomaterials, or gender-specific designs. For several of these
technologies, it is not clear whether they offer a significant
improvement in clinical outcomes over existing prostheses [63–
65]. However, as data from joint registries and head-to-head trials
uncover which specific implants can offer improved clinical
outcomes and/or reduced rates of revision, our model allows
decision makers to combine these outcomes data with the
implant’s marketed cost to determine whether such a device
would be cost-effective in particular patient populations.
While it is difficult to predict the benefit of an innovative TKA
implant to any one individual, the incremental benefit to society
appears modest, and the excess cost of using innovative implants
indiscriminately across populations could be substantial. Com-
pared to per capita healthcare expenditures among industrialized
nations, TKA alone is responsible for $3 billion in increased US
spending [66]. Targeting implants to specific populations based on
their expected clinical benefit may offer significant savings.
Moreover, TKA is representative of many medical devices,
ranging from hip and spinal implants, plates, screws and other
orthopedic hardware, to cataract and ophthalmologic implants,
which offer improvements in quality of life rather than survival
benefits. This work has implications for the development and
adoption of any medical device offering long-term clinical benefit
at a greater initial cost. Our analysis demonstrates that small
decreases in long-term device failure can provide clinical and
economic value under certain circumstances, but these innovations
may not offer equal benefit in all populations. In addition, many
innovative technologies offer improved long-term outcomes at the
expense of increased short-term complications due to increased
complexity of the procedure and/or the technical skill required to
optimally implement such advances. Our data suggest that even if
innovative implants lead to some increases in short-term
complications, the impact on overall cost-effectiveness will be
small in situations where innovative devices offer substantial
benefit over standard devices in reducing long term failure. In
situations where innovative implants are associated with lowering
rather than increasing short-term complications, cost-effectiveness
will likely be more favorable.
These results also provide important insights regarding the costs
and benefits associated with the diffusion of technology into
clinical practice. The modeling approach presented here can and
should focus and improve device development, identify optimal
populations for testing novel technologies, and provide physicians,
insurers and patients detailed information on the clinical benefits
expected for a given investment. The complex trade-offs between
short- and long-term health and economic consequences of
technological innovation cannot easily be captured by even the
most sophisticated randomized trials. Model-based evaluations
such as those presented here may provide important insights for
evaluating medical device innovation and merit consideration as a
standard component of the evaluation process.
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